Expanded access to COVID-19 oral antivirals for Aboriginal and Torres Strait Islander people

From Tuesday, 1 November, eligibility for COVID-19 oral treatments through the Pharmaceutical Benefits Scheme, has been widened so that Aboriginal and Torres Strait Islander people, aged 30 years or over, will require only one risk factor (from the current list of risk factors) instead of two, to meet the definition of high risk.

To support prompt treatment of patients as of 1 November 2022, medical practitioners and nurse practitioners will be able to add Lagevrio® and Paxlovid® to their Prescriber Bag supplies.

A complete list of current is available on the PBS website Pharmaceutical Benefits Scheme (PBS) | Prescriber Bag Supplies

Share this article